A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

NCT ID: NCT04476849

Last Updated: 2024-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-10
• Study Completion Date: 2022-03-11

Brief Summary

The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of fezolinetant and ES259564 (fezolinetant metabolite) in female participants with varying levels of renal impairment (mild, moderate and severe) compared to healthy female participants with normal renal function.

This study will also evaluate the safety and tolerability of a single oral dose of fezolinetant in female participants with varying levels of renal impairment (mild, moderate and severe) and healthy female participants with normal renal function.

Renal function will be measured by estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease (MDRD) formula: Mild (eGFR 60 to < 90 mL/min per 1.73 m^2) renal impairment; moderate (eGFR 30 to < 60 mL/min per 1.73 m^2) renal impairment, severe (eGFR < 30 mL/min per 1.73 m^2) renal impairment and not on hemodialysis and normal (eGFR ≥ 90 mL/min per 1.73 m^2) renal function.

Detailed Description

This study will be comprised of four groups of participants based on renal function. Participants will be screened for up to 28 days prior to investigational product (IP) administration on Day 1. Eligible participants with mild, moderate and severe renal function and healthy participants with normal renal function will be admitted to the clinical unit on Day -1 and will be residential for a single period of six days/five nights. On Day 1, participants will receive a single oral dose of fezolinetant under fasting conditions followed by a 96-hour in-house blood and urine sampling period. Participants are to remain awake, seated or semirecumbent and avoid lying on either the left or right side for at least four hours postdose. Standard safety and tolerability assessments will be conducted. Participants will be discharged from the clinical unit on Day 5 on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit.

The study will be completed with an end-of-study visit (ESV). The ESV will take place five to nine days after the last pharmacokinetic sample is collected or at early discontinuation from the study.

Conditions

Healthy Volunteers; Renal Impairment

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fezolinetant: Mild renal impairment

Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.

Group Type: EXPERIMENTAL

fezolinetant

Intervention Type: DRUG

Oral

Fezolinetant: Moderate renal impairment

Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.

Group Type: EXPERIMENTAL

fezolinetant

Intervention Type: DRUG

Oral

Fezolinetant: Severe renal impairment

Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.

Group Type: EXPERIMENTAL

fezolinetant

Intervention Type: DRUG

Oral

Fezolinetant: Normal renal function

Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.

Group Type: EXPERIMENTAL

fezolinetant

Intervention Type: DRUG

Oral

Interventions

fezolinetant

Oral

Intervention Type: DRUG

Other Intervention Names

ESN364

Eligibility Criteria

Inclusion Criteria

• Subject has a Body Mass Index (BMI) range of 18.5 to 40 kg/m^2, inclusive and weighs at least 50 kg at screening.
• Female subject is not pregnant and at least one of the following conditions apply:

• Not a woman of childbearing potential (WOCBP)
• WOCBP who agrees to follow the contraceptive guidance for at least 30 days prior to day -1 through at least 30 days after final IP administration
• Female subject must agree not to breastfeed starting at screening and throughout the study period and for 30 days after final IP administration.
• Female subject must not donate ova starting from administration of IP and throughout the study period and for 30 days after final IP administration.
• Subject has normal renal function as defined by estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease (MDRD) formula ≥ 90 milliliters per minute (mL/min) per 1.73 m^2 or subject has varying degrees of chronic kidney disease as defined by the National Kidney Foundation and by eGFR:

• 60 to < 90 mL/min per 1.73 m^2 for subject with mild renal impairment
• 30 to < 60 mL/min per 1.73 m^2 for subject with moderate renal impairment
• < 30 mL/min per 1.73 m^2 and not on hemodialysis for subject with severe renal impairment
• Subject has adequate venous access.
• Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion Criteria

• Subject has received any investigational therapy within 28 days or five half-lives, whichever is longer, prior to Day -1.
• Subject has any condition which makes the subject unsuitable for study participation.
• Female subject who has been pregnant within six months prior to screening or breastfeeding within 3 months prior to screening.
• Subject has a known or suspected hypersensitivity to fezolinetant or any components of the formulation used.
• Subject has had previous exposure with fezolinetant.
• Subject has any of the liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and total bilirubin [TBL]) ≥ 1.5 × the Upper Limit of Normal (ULN) on Day -1. In such a case, the assessment may be repeated once.
• Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration.
• Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 1 week prior to Day -1.
• Subject has smoked, used tobacco-containing products and nicotine or nicotine-containing products (e.g., electronic vapes) within six months prior to screening or the subject tests positive for cotinine at screening or on Day -1.
• Subject has a history of consuming > 7 units of alcoholic beverages per week within six months prior to screening or has a history of alcoholism three months prior to screening or drug/chemical/ substance abuse within one year prior to screening (note: 1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol at screening or on Day -1.
• Subject has used any inducer of cytochrome P450 (CYP) 1A2 in the three months prior or inhibitors of CYP 1A2 in the two weeks or five half-lives, whichever is longer, prior to Day -1.
• Subject has had significant blood loss, donated ≥ 1 unit (450 mL) of whole blood or donated plasma within seven days prior to Day -1 and/or received a transfusion of any blood or blood products within 60 days.
• Subject has a positive serology test for hepatitis A virus antibodies (immunoglobulin M), hepatitis B core antibodies, hepatitis B surface antigen, hepatitis C virus antibodies or antibodies to human immunodeficiency virus type 1 and/or type 2 at screening.
• Subject is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.

Additional criteria for subjects with renal impairment:

• Subject who has a history of any clinically significant illness (other than renal disease and conditions related to renal disease, such as stable diabetes and stable hypertension), medical condition or laboratory abnormality within 3 months prior to screening which precludes the subject from study participation.
• Subject has a mean pulse < 40 or > 90 beats per minutes (bpm); mean systolic blood pressure (SBP) < 90 or > 160 millimeters of mercury (mmHg); mean diastolic blood pressure (DBP) < 50 or > 100 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least five minutes; pulse will be measured automatically) on Day -1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken.
• Subject has a mean corrected QT interval using Fridericia's formula (QTcF) of > 480 msec on Day -1. If the mean QTcF exceeds the limits above, one additional triplicate ECG may be taken.
• Subject who has had a change in dose regimen of medically required medication(s) in the two weeks prior to IP administration (permitted concomitant medications) and/or subject for whom dose changes are likely to occur during the study (minor dose changes are allowed in agreement with the sponsor) and/or subject has used nonpermitted concomitant medication(s) (including vitamins, hormonal contraceptives, hormone replacement therapy [HRT] and natural and herbal remedies, e.g., St. John's Wort) in the three weeks prior to admission to the clinical unit.
• Subject who requires or is likely to require any new concomitant medications during the course of the study.
• Subject who has a renal disease secondary to malignancy.
• Subject who has a fluctuating or rapidly deteriorating renal function within four weeks prior to IP administration, as indicated by strongly varying or worsening clinical and/or laboratory signs of renal impairment within the screening period.
• Subject has a hemoglobin result of < 9 grams per deciliter.
• Subject has a functioning kidney transplant.
• Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within three months prior to Day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) at screening or on Day -1, unless the positive result is due to an approved prescription medication.

Additional criteria for healthy subjects with normal renal function:

• Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.
• Subject has any clinically significant abnormality following the physical examination, ECG and protocol-defined clinical laboratory tests at screening or on Day -1.
• Subject has a mean pulse < 45 or > 90 bpm; mean SBP > 150 mmHg; mean DBP > 90 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least 5 minutes; pulse will be measured automatically) on Day -1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken.
• Subject has a mean QTcF of > 450 msec on Day -1. If the mean QTcF exceeds the limits above, one additional triplicate ECG may be taken.
• Subject has used any prescribed or nonprescribed drugs (including vitamins, hormonal contraceptives, HRT and natural and herbal remedies, e.g., St. John's Wort) in the two weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day).
• Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within three months prior to Day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) at screening or on Day -1.
• Subject has creatinine level outside normal limits on Day -1. In such a case, the assessment may be repeated once.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Astellas Pharma Global Development, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Executive Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Global Development, Inc.

Locations

National Institute of Clinical Research

Garden Grove, California, United States

Inland Empire Clinical Trials, LLC

Rialto, California, United States

Clinical Research of West Florida, Inc.

Clearwater, Florida, United States

Accel Research Sites - DeLand Clinical Research Unit

DeLand, Florida, United States

Clinical Pharmacology of Miami, LLC

Miami, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

Prism research, LLC

Saint Paul, Minnesota, United States

Countries

United States

Other Identifiers

2693-CL-0008

Identifier Type: -

Identifier Source: org_study_id